China Coronary Stents Market Size, Share and Trends Analysis Report by Product (Bare Metal Stents (BMS), Drug Eluting Stents (DES), Bioresorbable Vascular Scaffold) 2024-2030

The China coronary stents market size was estimated at USD 657.7 million in 2023 and is projected to grow at a CAGR of 6.9% from 2024 to 2030. The market is experiencing significant growth driven by a combination of factors including the rising prevalence of cardiovascular diseases, an aging population, advancements in medical technology, and increasing healthcare expenditure. As lifestyle-related risk factors such as obesity, diabetes, and hypertension become more prevalent among the Chinese population, the demand for effective interventional cardiology solutions has surged. The Chinese government’s initiatives to improve healthcare infrastructure and access to advanced medical devices have facilitated market expansion.

The rapid pace of technological advancements in the medical device sector is a significant driver for the coronary stents market in China. Innovations such as drug-eluting stents (DES) and bioresorbable vascular scaffolds (BVS) have transformed treatment options for patients with coronary artery disease (CAD). These advanced stents offer improved performance, reduced risk of restenosis, and enhanced patient outcomes. In April 2024, the RESOLUTE ONYX China Single Arm Study evaluated the safety and efficacy of the Medtronic Resolute Onyx zotarolimus-eluting coronary stent system in patients eligible for percutaneous transluminal coronary angioplasty (PTCA), focusing on de novo lesions treatable with the Resolute Onyx Stent System in China. As manufacturers invest in research and development to create more effective and safer products, the adoption of these technologies is expected to increase, thereby driving market growth. China has seen a notable rise in cardiovascular diseases due to lifestyle changes, urbanization, and an aging population. In June 2023, a study in the Journal of Geriatric Cardiology showed that cardiovascular diseases affect about 330 million Chinese, with major conditions including 13 million strokes, 11.39 million with coronary heart disease, 8.9 million heart failures, and others such as pulmonary heart disease, atrial fibrillation, rheumatic heart disease, and congenital heart disease. Factors such as poor dietary habits, sedentary lifestyles, and increased stress levels contribute to this trend. The growing incidence of conditions such as hypertension, obesity, and diabetes further exacerbates the situation. Consequently, there is an increasing demand for effective treatment options such as coronary stenting procedures.

The Chinese government has been actively promoting healthcare reforms aimed at improving access to medical services and enhancing the quality of care. Initiatives such as favorable reimbursement policies for cardiac procedures and investments in healthcare infrastructure are encouraging hospitals and clinics to adopt advanced medical technologies, including coronary stents. Regulatory bodies are streamlining approval processes for new devices, making it easier for manufacturers to bring innovative products to market. This supportive environment fosters growth within the coronary stents sector. In March 2024, the National Healthcare Security Administration noted that China's initiative to centralize procurement significantly reduced heart stent prices by over 90%, simultaneously fostering the uptake of cutting-edge products and broadening the availability of stent implantation procedures. This initiative culminated in an average 93 percent reduction in prices, bringing the cost of each stent down to between USD 98.31 to USD 112.35.

China Coronary Stents Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the China coronary stents market report based on product:

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Bare Metal Stents (BMS)
• Drug-Eluting Stents (DES)
• Biodegradable
• Non-Biodegradable
• Bioresorbable Vascular Scaffold

The leading players in the China Coronary Stents market include:

• Abbott
• Medtronic
• Boston Scientific Corporation
• Biotronik
• MicroPort Scientific Corporation
• Lepu Medical Technology(Beijing) Co.,Ltd
• Biosensors
• Sino Medical Science and Technology Co., Ltd
• Terumo Corporation
• Shenzhen Salubris Pharmaceuticals Co., Ltd

Why should you buy this report?

• Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
• Competitive Landscape: Explore the market presence of key players worldwide.
• Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
• Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

• Market intelligence to enable effective decision-making
• Market estimates and forecasts from 2018 to 2030
• Growth opportunities and trend analyses
• Segment and regional revenue forecasts for market assessment
• Competition strategy and market share analysis
• Product innovation listing for you to stay ahead of the curve
• COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.